Vascular-disrupting agents in oncology

Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study

(2017) R. Pili et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.

(2017) J. A. Sosa et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial.

(2017) E. B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

(2017) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Lectures

(2012)   ANNALS OF ONCOLOGY

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study

(2012) Fairooz F. Kabbinavar et al.   EUROPEAN JOURNAL OF CANCER

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

(2011) M. Zweifel et al.   ANNALS OF ONCOLOGY

Bevacizumab and ovarian cancer

(2011) Shinya Sato et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Modeling of angioadaptation: insights for vascular development

(2011) Axel R. Pries et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors

(2011) Thierry Marysael et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?

(2011) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer

(2010) A.-M. Tsimberidou et al.   MOLECULAR CANCER THERAPEUTICS

AVE8062: a new combretastatin derivative vascular disrupting agent

(2009) Angelo Delmonte et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab

(2009) Alan B. Sandler et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2009) Mark J. McKeage et al.   LUNG CANCER

Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer

(2009) C. Gridelli et al.   ONCOLOGIST

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2008) M J McKeage et al.   BRITISH JOURNAL OF CANCER

Distinct signaling pathways of microtubule inhibitors - vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively

(2008) Sergey N. Kolomeichuk et al.   FEBS Journal

Medical Care in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

(2008) Paul C. Nathan et al.   JOURNAL OF CLINICAL ONCOLOGY